Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient.
This case report presents the pharmacokinetics of doxorubicin and etoposide in a 14-year-old morbidly obese (body mass index: 46.3 kg/m2) male patient with Hodgkin disease. Dosing based on an adjusted body surface area resulted in a dose reduction by approximately 25% as compared to dosing based on actual body surface area. Plasma clearance of doxorubicin as well as plasma clearance and elimination rate of etoposide for this patient was comparable to pharmacokinetic data from nonobese pediatric patients. The therapy was well tolerated without any specific toxicity and a complete response was obtained after 2 scheduled courses, with the patient in complete remission 25 months after end of treatment.
Ritzmo
Carina
C
Karolinska Pharmacy and Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden.
Söderhäll
Stefan
S
Karlén
Jonas
J
Nygren
Helen
H
Eksborg
Staffan
S
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015992:Body Mass Index; D001830:Body Surface Area; D004317:Doxorubicin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005047:Etoposide / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D009767:Obesity, Morbid / Q000150:complications / Q000378:metabolism*; D012074:Remission Induction
D005047:Etoposide; D004317:Doxorubicin